Genome-resolved metagenomics reveals population-dependent gut microbiome responses to albendazole-ivermectin treatment
En palabras de los autores
Soil-transmitted helminth control relies on mass anthelmintic treatment, yet helminth-anthelmintic-microbiome interactions and their role on treatment response remain poorly understood. We characterised the microbiome, resistome, and functional profiles of 858 paired stool metagenomes from 429 children treated with albendazole or a fixed-dose albendazole-ivermectin co-formulation in the ALIVE clinical trial in Ethiopia and Mozambique. Baseline microbiome composition differed more by country than infection status and was not associated with albendazole efficacy or adverse events. Co-formulation treatment, particularly three consecutive daily doses, was associated with depletion of Enterobacteriaceae, predominantly Escherichia coli, in Ethiopia, with reductions in E. coli-associated resistance genes and metabolic pathways. Genome-resolved analyses of over 22,000 high-quality metagenome-assembled genomes confirmed this depletion across multiple E. coli strain-level populations, linking taxonomic, resistome, and functional signals to one ecological event. These findings reveal an off-target effect of combination anthelmintic treatment relevant to large-scale deworming programmes and expand genomic resources for African gut microbiota.
Apareció: jueves, 19 de noviembre. medRxiv. Preprint, todavía sin revisión por pares.